Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-transplant Cyclophosphamide with Busulfan/Fludarabine for GVHD Prophylaxis
NCT00800839Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2008
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in graft-versus-host disease (GVHD), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Cumulative Incidence of Grade II to IV Acute GVHD at 100 days, Cumulative Incidence of Grade III to IV Acute GVHD at 100 days and 1 more. Started Sep 2008; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00800839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00800839.